Phase 1, Open-Label, Non-Randomized, Single-Center, Single-Dose Study to Assess the Pharmacokinetics & Safety of ANT3310 Combined With Meropenem Administered as a Single Intravenous Infusion to Adult Subjects With Renal Function Impairment
This is an open-label, non-randomized, single-center, single i.v. dose Phase 1 trial to evaluate the pharmacokinetics and safety of a combination of ANT3310 and meropenem in participants with different degrees of renal function impairment, including participants with End-Stage Renal Disease (ESRD), compared with matching control participants with normal renal function.
Effect of a Synbiotic on Body Fat Mass, Weight Management, Traits of Metabolic Syndrome and Gut Permeability in Individuals With Abdominal Overweight: a Randomised, Controlled, Double-blind Clinical Study
In this placebo-controlled trial the effect of a synbiotic consisting of three different strains of Lactobacillus fermentum and acacia gum (gum arabic) was compared with a probiotic formulation containing identical strains on body fat mass, body weight management, traits of metabolic syndrome and gut permeability in individuals who are abdominally overweight.
Randomised, Controlled, Double-blind Clinical Study on the Effect of a Synbiotic on Body Fat Mass, Weight Management, Metabolic Syndrome and Other Risk Factors for CVD and Diabetes, on Fecal Microbiota and Adverse Effects
In this trial the effect of a synbiotic consisting of the three different strains of Lactobacillus fermentum and acacia gum (gum arabic) on body fat mass, body weight, long-term glycemia, insulin resistance and other risk factors for CVD and diabetes in overweight type 2 diabetics is investigated.
100 项与 Clinical Research Advantage, Inc. 相关的临床结果
0 项与 Clinical Research Advantage, Inc. 相关的专利(医药)
100 项与 Clinical Research Advantage, Inc. 相关的药物交易
100 项与 Clinical Research Advantage, Inc. 相关的转化医学